Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk

  • Authors:
    • Rakesh Singal
    • Larry Ferdinand
    • Partha M. Das
    • Isildinha M. Reis
    • James J. Schlesselman
  • View Affiliations

  • Published online on: November 1, 2004     https://doi.org/10.3892/ijo.25.5.1465
  • Pages: 1465-1471
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Methylenetetrahydrofolate reductase (MTHFR) catalyzes the synthesis of 5-methyltetrahydrofolate, which is involved in the methylation of homocysteine to methionine. Genetic polymorphisms that decrease MTHFR activity result in an altered cancer risk depending on folic acid intake. In this study we examined the C677T and A1298C polymorphisms of the MTHFR gene in specimens from 81 patients with prostate cancer and 42 controls selected from patients with benign prostatic hypertrophy (BPH). Genomic DNA was isolated from archived formaldehyde-fixed and paraffin-embedded tissue blocks. MTHFR genotypes were determined by restriction-fragment-length-polymorphism polymerase chain reaction. The MTHFR polymorphism frequencies in the prostate-cancer and BPH specimens were, respectively, 60% and 48% for 677CC, 31% and 48% for 677CT, 9% and 5% for 677TT, 36% and 43% for 1298AA, 53% and 40% for 1298AC, and 11% and 17% for 1298CC. Although such differences fall within the realm of chance variation (P>0.05), the data suggest that the 677CT genotype may be associated with a reduced risk of prostate cancer: the age-adjusted odds ratio (aOR) was 0.6 [95% confidence interval (CI): 0.3-1.4]; the odds-ratio reduction was similar in both blacks and whites (aOR=0.4 in blacks, and 0.6 in whites); and when polymorphisms at the 677 and 1298 loci were analyzed in conjunction, a lower frequency of the 677CT-1298AA genotype was observed in the patients with prostate cancer (aOR=0.3, 95% CI: 0.1-1.1). This particular genotype, moreover, was associated with lower Gleason score tumors (aOR=0.1 for Gleason-score 7 versus 6 tumors, 95% CI: 0.0-0.7) and earlier stage disease (aOR=0.3 for stage III versus II, 95% CI: 0.3-2.6). These findings suggest that polymorphisms of the MTHFR gene may alter the risk of developing prostate cancer.

Related Articles

Journal Cover

November 2004
Volume 25 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Singal R, Ferdinand L, Das PM, Reis IM and Schlesselman JJ: Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol 25: 1465-1471, 2004.
APA
Singal, R., Ferdinand, L., Das, P.M., Reis, I.M., & Schlesselman, J.J. (2004). Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. International Journal of Oncology, 25, 1465-1471. https://doi.org/10.3892/ijo.25.5.1465
MLA
Singal, R., Ferdinand, L., Das, P. M., Reis, I. M., Schlesselman, J. J."Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk". International Journal of Oncology 25.5 (2004): 1465-1471.
Chicago
Singal, R., Ferdinand, L., Das, P. M., Reis, I. M., Schlesselman, J. J."Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk". International Journal of Oncology 25, no. 5 (2004): 1465-1471. https://doi.org/10.3892/ijo.25.5.1465
a